<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Castro BE</submitter><funding>NIAID NIH HHS</funding><pagination>2424-2431</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7443737</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>75(9)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Vancomycin is a common first-line option for MRSA infections. The heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) phenotype is associated with therapeutic failure. However, hVISA isolates are usually reported as vancomycin susceptible by routine susceptibility testing procedures.&lt;h4>Objectives&lt;/h4>To detect and characterize the hVISA phenotype in MRSA isolates causing infections in nine Latin American countries.&lt;h4>Methods&lt;/h4>We evaluated a total of 1189 vancomycin-susceptible MRSA isolates recovered during 2006-08 and 2011-14. After an initial screening of hVISA using glycopeptide-supplemented agar strategies, the detection of hVISA was performed by Etest (GRD) and Macro-method (MET). Isolates deemed to be hVISA were subjected to population analysis profile/AUC (PAP/AUC) and WGS for further characterization. Finally, we interrogated alterations in predicted proteins associated with the development of the VISA phenotype in both hVISA and vancomycin-susceptible S. aureus (VSSA) genomes.&lt;h4>Results&lt;/h4>A total of 39 MRSA isolates (3.3%) were classified as hVISA (1.4% and 5.6% in MRSA recovered from 2006-08 and 2011-14, respectively). Most of the hVISA strains (95%) belonged to clonal complex (CC) 5. Only 6/39 hVISA isolates were categorized as hVISA by PAP/AUC, with 6 other isolates close (0.87-0.89) to the cut-off (0.9). The majority of the 39 hVISA isolates exhibited the Leu-14→Ile (90%) and VraT Glu-156→Gly (90%) amino acid substitutions in WalK. Additionally, we identified 10 substitutions present only in hVISA isolates, involving WalK, VraS, RpoB and RpoC proteins.&lt;h4>Conclusions&lt;/h4>The hVISA phenotype exhibits low frequency in Latin America. Amino acid substitutions in proteins involved in cell envelope homeostasis and RNA synthesis were commonly identified. Our results suggest that Etest-based methods are an important alternative for the detection of hVISA clinical isolates.</pubmed_abstract><journal>The Journal of antimicrobial chemotherapy</journal><pubmed_title>Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America.</pubmed_title><pmcid>PMC7443737</pmcid><funding_grant_id>R01 AI134637</funding_grant_id><funding_grant_id>R21 AI143229</funding_grant_id><funding_grant_id>K24 AI121296</funding_grant_id><pubmed_authors>Rios R</pubmed_authors><pubmed_authors>Dinh A</pubmed_authors><pubmed_authors>Millan LV</pubmed_authors><pubmed_authors>Vargas ML</pubmed_authors><pubmed_authors>Forero E</pubmed_authors><pubmed_authors>Hernandez AK</pubmed_authors><pubmed_authors>Reyes J</pubmed_authors><pubmed_authors>Castro BE</pubmed_authors><pubmed_authors>Rincon S</pubmed_authors><pubmed_authors>Berrio M</pubmed_authors><pubmed_authors>Diaz L</pubmed_authors><pubmed_authors>Carvajal LP</pubmed_authors><pubmed_authors>Seas C</pubmed_authors><pubmed_authors>Cubides P</pubmed_authors><pubmed_authors>Munita JM</pubmed_authors><pubmed_authors>Arias CA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America.</name><description>&lt;h4>Background&lt;/h4>Vancomycin is a common first-line option for MRSA infections. The heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) phenotype is associated with therapeutic failure. However, hVISA isolates are usually reported as vancomycin susceptible by routine susceptibility testing procedures.&lt;h4>Objectives&lt;/h4>To detect and characterize the hVISA phenotype in MRSA isolates causing infections in nine Latin American countries.&lt;h4>Methods&lt;/h4>We evaluated a total of 1189 vancomycin-susceptible MRSA isolates recovered during 2006-08 and 2011-14. After an initial screening of hVISA using glycopeptide-supplemented agar strategies, the detection of hVISA was performed by Etest (GRD) and Macro-method (MET). Isolates deemed to be hVISA were subjected to population analysis profile/AUC (PAP/AUC) and WGS for further characterization. Finally, we interrogated alterations in predicted proteins associated with the development of the VISA phenotype in both hVISA and vancomycin-susceptible S. aureus (VSSA) genomes.&lt;h4>Results&lt;/h4>A total of 39 MRSA isolates (3.3%) were classified as hVISA (1.4% and 5.6% in MRSA recovered from 2006-08 and 2011-14, respectively). Most of the hVISA strains (95%) belonged to clonal complex (CC) 5. Only 6/39 hVISA isolates were categorized as hVISA by PAP/AUC, with 6 other isolates close (0.87-0.89) to the cut-off (0.9). The majority of the 39 hVISA isolates exhibited the Leu-14→Ile (90%) and VraT Glu-156→Gly (90%) amino acid substitutions in WalK. Additionally, we identified 10 substitutions present only in hVISA isolates, involving WalK, VraS, RpoB and RpoC proteins.&lt;h4>Conclusions&lt;/h4>The hVISA phenotype exhibits low frequency in Latin America. Amino acid substitutions in proteins involved in cell envelope homeostasis and RNA synthesis were commonly identified. Our results suggest that Etest-based methods are an important alternative for the detection of hVISA clinical isolates.</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Sep</publication><modification>2022-02-10T15:43:52.723Z</modification><creation>2022-02-10T15:43:52.723Z</creation></dates><accession>S-EPMC7443737</accession><cross_references><pubmed>32562543</pubmed><doi>10.1093/jac/dkaa221</doi></cross_references></HashMap>